Labcorp (LH) Expected to Announce Earnings on Thursday

Labcorp (NYSE:LH) is expected to be issuing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $4.79 per share and revenue of $3.7094 billion for the quarter. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 9:00 AM ET.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the prior year, the business earned $3.84 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. On average, analysts expect Labcorp to post $18 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Labcorp Stock Up 0.9%

LH stock opened at $281.85 on Thursday. The stock’s 50 day simple moving average is $267.72 and its 200 day simple moving average is $268.63. The company has a market cap of $23.11 billion, a P/E ratio of 24.96, a price-to-earnings-growth ratio of 1.85 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $293.72.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s dividend payout ratio is presently 25.51%.

Insider Activity

In other news, EVP Bryan T. Vaughn sold 234 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. This trade represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,991 shares of company stock valued at $1,796,696 in the last ninety days. 0.84% of the stock is currently owned by insiders.

Institutional Trading of Labcorp

Hedge funds have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC purchased a new stake in shares of Labcorp during the 3rd quarter worth approximately $28,000. DV Equities LLC bought a new stake in shares of Labcorp in the 4th quarter worth approximately $29,000. EFG International AG purchased a new position in Labcorp in the fourth quarter valued at approximately $33,000. Headlands Technologies LLC lifted its stake in Labcorp by 300.0% in the second quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 96 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Labcorp by 575.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 162 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 138 shares during the period. Institutional investors own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LH shares. Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Bank of America raised their price objective on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Finally, Robert W. Baird lifted their price objective on shares of Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp has an average rating of “Moderate Buy” and an average target price of $314.40.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.